## Arjun D Law

## List of Publications by Citations

Source: https://exaly.com/author-pdf/6822293/arjun-d-law-publications-by-citations.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

488 19 90 12 g-index h-index citations papers 106 715 3.3 3.73 L-index avg, IF ext. citations ext. papers

#	Paper	IF	Citations
90	A phase I trial of NK-92 cells for refractory hematological malignancies relapsing after autologous hematopoietic cell transplantation shows safety and evidence of efficacy. <i>Oncotarget</i> , <b>2017</b> , 8, 89256-8	39 <b>2</b> 68	89
89	Reduced-Intensity Conditioning and Dual T Lymphocyte Suppression with Antithymocyte Globulin and Post-Transplant Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Haploidentical Hematopoietic Stem Cell Transplants for Hematological Malignancies. <i>Biology of Blood and Marrow</i>	4.7	36
88	Transplantation, <b>2018</b> , 24, 2259-2264 Antibody Therapies for Acute Myeloid Leukemia: Unconjugated, Toxin-Conjugated, Radio-Conjugated and Multivalent Formats. <i>Journal of Clinical Medicine</i> , <b>2019</b> , 8,	5.1	26
87	Emerging therapies for acute myeloid leukemia: translating biology into the clinic. <i>JCI Insight</i> , <b>2017</b> , 2,	9.9	21
86	Relapsing polychondritis: clinical presentations, disease activity and outcomes. <i>Orphanet Journal of Rare Diseases</i> , <b>2014</b> , 9, 198	4.2	21
85	Low rates of acute and chronic GVHD with ATG and PTCy in matched and mismatched unrelated donor peripheral blood stem cell transplants. <i>European Journal of Haematology</i> , <b>2019</b> , 102, 486-493	3.8	18
84	Prognostic significance of pre-transplant quality of life in allogeneic hematopoietic cell transplantation recipients. <i>Bone Marrow Transplantation</i> , <b>2015</b> , 50, 1235-40	4.4	17
83	Pregnancy: part of life in chronic myelogenous leukemia. <i>Leukemia and Lymphoma</i> , <b>2017</b> , 58, 280-287	1.9	16
82	Myeloid Sarcoma: An Unusual Case of Mediastinal Mass and Malignant Pleural Effusion with Review of Literature. <i>Indian Journal of Hematology and Blood Transfusion</i> , <b>2015</b> , 31, 466-71	0.7	16
81	Dual T-cell depletion with ATG and PTCy for peripheral blood reduced intensity conditioning allo-HSCT results in very low rates of GVHD. <i>Bone Marrow Transplantation</i> , <b>2020</b> , 55, 1773-1783	4.4	14
80	Safety and Efficacy of Haploidentical Peripheral Blood Stem Cell Transplantation for Myeloid Malignancies Using Post-transplantation Cyclophosphamide and Anti-thymocyte Globulin as GraftHost Disease Prophylaxis. <i>Clinical Hematology International</i> , <b>2019</b> , 1, 105-113	1.8	14
79	Primary bone marrow lymphoma is a rare neoplasm with poor outcome: case series from single tertiary care centre and review of literature. <i>Hematological Oncology</i> , <b>2016</b> , 34, 42-8	1.3	14
78	Cellular immunotherapy for acute myeloid leukemia: How specific should it be?. <i>Blood Reviews</i> , <b>2019</b> , 35, 18-31	11.1	12
77	Reduced intensity allogeneic stem cell transplant with anti-thymocyte globulin and post-transplant cyclophosphamide in acute myeloid leukemia. <i>European Journal of Haematology</i> , <b>2019</b> , 103, 510-518	3.8	10
76	Pilot prospective study of Frailty and Functionality in routine clinical assessment in allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , <b>2021</b> , 56, 60-69	4.4	10
75	Autologous Stem Cell Transplantation for Multiple Myeloma: Single Centre Experience from North India. <i>Indian Journal of Hematology and Blood Transfusion</i> , <b>2018</b> , 34, 261-267	0.7	10
74	Vitamin D deficiency in adult patients with ulcerative colitis: Prevalence and relationship with disease severity, extent, and duration. <i>Indian Journal of Gastroenterology</i> , <b>2019</b> , 38, 6-14	1.9	9

## (2020-2020)

73	Anticoagulation prophylaxis reduces venous thromboembolism rate in adult acute lymphoblastic leukaemia treated with asparaginase-based therapy. <i>British Journal of Haematology</i> , <b>2020</b> , 191, 748-754	4.5	9	
72	Characteristics, treatment and outcomes of nontuberculous mycobacterial pulmonary disease after allogeneic haematopoietic stem cell transplant. <i>European Respiratory Journal</i> , <b>2018</b> , 51,	13.6	8	
71	Eosinophilic vasculitis: time for recognition of a new entity?. <i>Indian Journal of Hematology and Blood Transfusion</i> , <b>2014</b> , 30, 325-30	0.7	7	•
70	Indian common krait envenomation presenting as coma and hypertension: A case report and literature review. <i>Journal of Emergencies, Trauma and Shock</i> , <b>2014</b> , 7, 126-8	1.2	7	
69	Successful treatment of aortic root dilatation in a patient with relapsing polychondritis. <i>Clinical Rheumatology</i> , <b>2013</b> , 32 Suppl 1, S59-61	3.9	7	
68	Reduced-intensity conditioning allogeneic transplant with dual T-cell depletion in myelofibrosis. <i>European Journal of Haematology</i> , <b>2019</b> , 103, 597-606	3.8	6	
67	Methotrexate induced lung injury in a patient with primary CNS lymphoma: a case report. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , <b>2012</b> , 4, e2012020	3.2	6	
66	Clinical prevalence and outcome of cardiovascular events in the first 100 days postallogeneic hematopoietic stem cell transplant. <i>European Journal of Haematology</i> , <b>2021</b> , 106, 32-39	3.8	6	
65	Fresh vs. frozen allogeneic peripheral blood stem cell grafts: A successful timely option. <i>American Journal of Hematology</i> , <b>2021</b> , 96, 179-187	7.1	6	
64	Epstein-barr virus infection masquerading as acute leukemia: a report of two cases and review of literature. <i>Indian Journal of Hematology and Blood Transfusion</i> , <b>2014</b> , 30, 26-8	0.7	5	
63	Impact of central nervous system involvement in AML on outcomes after allotransplant and utility of pretransplant cerebrospinal fluid assessment. <i>European Journal of Haematology</i> , <b>2019</b> , 103, 483-490	3.8	4	
62	Anticoagulation Prophylaxis with Weight-Adjusted Enoxaparin Reduces Rates of Venous Thromboembolism in Patients with Acute Lymphoblastic Leukemia Receiving Asparaginase-Based Intensification Therapy. <i>Blood</i> , <b>2018</b> , 132, 3974-3974	2.2	4	
61	Allogeneic stem cell transplant in myelodysplastic syndrome-factors impacting survival. <i>European Journal of Haematology</i> , <b>2020</b> , 104, 116-124	3.8	4	
60	"Unusual Cause Of Tophi With Renal Thrombotic Microangiopathy". <i>Indian Journal of Hematology and Blood Transfusion</i> , <b>2016</b> , 32, 100-3	0.7	3	
59	Influence of FLT3-ITD and NPM1 status on allogeneic hematopoietic cell transplant outcomes in patients with cytogenetically normal AML. <i>European Journal of Haematology</i> , <b>2019</b> , 102, 368-374	3.8	3	
58	Post-transplant cyclophosphamide combined with anti-thymocyte globulin for graft-vs-host disease prophylaxis improves survival and lowers non-relapse mortality in older patients undergoing allogeneic hematopoietic cell transplantation. <i>Annals of Hematology</i> , <b>2020</b> , 99, 1377-1387	3	3	
57	Pilot Study on Frailty and Functionality on Routine Clinical Assessment in Allogeneichematopoietic Cell Transplantation to Predict Outcomes. <i>Blood</i> , <b>2019</b> , 134, 380-380	2.2	3	
56	High incidence but low mortality of EBV-reactivation and PTLD after alloHCT using ATG and PTCy for GVHD prophylaxis. <i>Leukemia and Lymphoma</i> , <b>2020</b> , 61, 3198-3208	1.9	3	

55	Azacitidine maintenance after allogeneic hematopoietic cell transplantation for MDS and AML. <i>Blood Advances</i> , <b>2021</b> , 5, 1757-1759	7.8	3
54	Fanconi Syndrome: A Rare Initial Presentation of Acute Lymphoblastic Leukemia. <i>Indian Journal of Hematology and Blood Transfusion</i> , <b>2016</b> , 32, 5-7	0.7	2
53	Dual T Cell Depletion with Anti-Thymocyte Globulin and Post-Transplant Cyclophosphamide Results in Low Rates of Cytokine Release Syndrome in Peripheral Blood Haplo-Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2019</b> , 25, e387-e388	4.7	2
52	Air in the heart: what should one do?. American Journal of Emergency Medicine, 2012, 30, 1659.e1-3	2.9	2
51	Steroid Responsive Parenchymal Lung Involvement and Acute Renal Failure in a Patient with Relapsing Polychondritis. <i>Journal of Postgraduate Medicine Education and Research</i> , <b>2012</b> , 46, 198-201	0.1	2
50	Impact of CD34+ cell dose on reduced intensity conditioning regimen haploidentical hematopoietic stem cell transplantation. <i>European Journal of Haematology</i> , <b>2020</b> , 104, 36-45	3.8	2
49	Prognostic impact of the adverse molecular-genetic profile on long-term outcomes following allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia. <i>Bone Marrow Transplantation</i> , <b>2021</b> , 56, 1908-1918	4.4	2
48	Efficacy and cost analysis of eltrombopag in thrombocytopenia and poor graft function post allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , <b>2021</b> , 56, 2471-2476	4.4	2
47	Post-Transplant Cyclophosphamide Combined with Anti-Thymocyte Globulin as Graft-versus-Host Disease Prophylaxis for Allogeneic Hematopoietic Cell Transplantation in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome. <i>Acta Haematologica</i> , <b>2021</b> , 144, 66-73	2.7	2
46	Post-transplant ferritin level predicts outcomes after allogeneic hematopoietic stem cell transplant, independent from pre-transplant ferritin level. <i>Annals of Hematology</i> , <b>2021</b> , 100, 789-798	3	2
45	Association of Factors Influencing Selection of Upfront Hematopoietic Cell Transplantation versus Nontransplantation Therapies in Myelofibrosis. <i>Transplantation and Cellular Therapy</i> , <b>2021</b> , 27, 600.e1-6	500.e8	2
44	L-PROBe: A Novel Non-anthracycline Combination Chemotherapy Regimen for Aggressive B Cell Non-Hodgkin Lymphoma in Elderly Patients. <i>Indian Journal of Hematology and Blood Transfusion</i> , <b>2017</b> , 33, 61-68	0.7	1
43	Sequential liver and haematopoietic stem cell transplantation in a case of fulminant hepatitis associated liver failure and aplastic anaemia. <i>European Journal of Haematology</i> , <b>2019</b> , 102, 375-377	3.8	1
42	Combination of the Centre for International Blood and Marrow Transplant Registry Risk Score and the Global Severity Score Enhances Prognostic Risk Stratification in Patients Receiving Frontline Therapy for Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , <b>2019</b> ,	4.7	1
41	Less Is More: Superior Graft-versus-Host Disease-Free/Relapse-Free Survival with Reduced-Intensity Conditioning and Dual T Cell Depletion in Acute Myelogenous Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , <b>2020</b> , 26, 1511-1519	4.7	1
40	Outcomes of therapy-related acute lymphoblastic leukemia in adults after allogeneic stem cell transplantation. <i>European Journal of Haematology</i> , <b>2020</b> , 105, 24-29	3.8	1
39	Epstein-Barr virus associated post-transplant lymphoproliferative disorder mimicking acute graft versus host disease. <i>European Journal of Haematology</i> , <b>2019</b> , 103, 519-522	3.8	1
38	Management of hypereosinophilia in tropical settings. <i>Medical Journal Armed Forces India</i> , <b>2015</b> , 71, 60-	<b>6</b> 1.9	1

## (2011-2020)

37	Efficacy and Cost Analysis of Eltrombopag in Thrombocytopenia and Poor Graft Function Post Allogeneic Hematopoietic Cell Transplantation in a Canadian Centre - a Prospective Observational Study. <i>Blood</i> , <b>2020</b> , 136, 18-18	2.2	1	
36	Allogeneic Stem Cell Transplantation Has Limited Benefit in Older Patients with Mixed Phenotype Acute Leukemia. <i>Blood</i> , <b>2019</b> , 134, 5725-5725	2.2	1	
35	Anticoagulation Prophylaxis in Asparaginase-Based Therapy in Adults with Acute Lymphoblastic Leukemia. <i>Blood</i> , <b>2016</b> , 128, 1453-1453	2.2	1	
34	Clinical Experience in the Randomized Phase 3 Sierra Trial: Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] Conditioning Enables Hematopoietic Cell Transplantation with Successful Engraftment and Acceptable Safety in Patients with Active, Relapsed/Refractory AML Not Responding to	2.2	1	
33	Anti-thymocyte globulin and post-transplant cyclophosphamide predisposes to inferior outcome when using cryopreserved stem cell grafts. <i>European Journal of Haematology</i> , <b>2022</b> , 108, 61-72	3.8	1	
32	Experience Using Anti-Thymocyte Globulin With Post-Transplantation Cyclophosphamide for Graft-Versus-Host Disease Prophylaxis in Peripheral Blood Haploidentical Stem Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , <b>2021</b> , 27, 428.e1-428.e9		1	
31	Comparison of the Prognostic Ability of the HCT-CI, the Modified EBMT, and the EBMT-ADT Pre-transplant Risk Scores for Acute Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2021</b> , 21, e559-e568	2	1	
30	Effect of donor age and kinship on outcomes in haplo-identical stem cell transplantation may be modulated by GVHD prophylaxis strategies. <i>Bone Marrow Transplantation</i> , <b>2021</b> , 56, 689-691	4.4	1	
29	Prolactin, a potential biomarker for chronic GVHD activity. <i>European Journal of Haematology</i> , <b>2021</b> , 106, 158-164	3.8	1	
28	Multicenter, Retrospective Evaluation of Therapeutic Efficacy of Ruxolitinib for Chronic Gvhd Treatment. <i>Blood</i> , <b>2020</b> , 136, 45-47	2.2	O	
27	Risk of Thrombosis in Adult Philadelphia-Positive ALL Treated with an Asparaginase-Free ALL Regimen. <i>Current Oncology</i> , <b>2020</b> , 28, 128-137	2.8	0	
26	Pretransplant bone marrow cellularity and blood count recovery are not associated with relapse or survival risk following allogeneic stem cell transplant for AML in CR. <i>European Journal of Haematology</i> , <b>2021</b> , 107, 354-363	3.8	O	
25	Effect of pre-transplant JAK1/2 inhibitors and CD34 dose on transplant outcomes in myelofibrosis. <i>European Journal of Haematology</i> , <b>2021</b> , 107, 517-528	3.8	0	
24	Outcomes of adult patients with acute myeloid leukemia and unsuccessful cytogenetic analysis undergoing allogeneic hematopoietic stem cell transplantation. <i>Hematology/ Oncology and Stem Cell Therapy</i> , <b>2021</b> , 14, 134-140	2.7	O	
23	Lower dose of ATG combined with post-transplant cyclophosphamide for HLA matched RIC alloHCT is associated with effective control of GVHD and less viral infections. <i>Leukemia and Lymphoma</i> , <b>2021</b> , 1-11	1.9	0	
22	Hypereosinophilia in a Young Patient: Occamß Razor or Hickamß Dictum?. <i>Indian Journal of Hematology and Blood Transfusion</i> , <b>2016</b> , 32, 340-3	0.7		
21	Reply to letter to the editor. <i>Leukemia and Lymphoma</i> , <b>2017</b> , 58, 1273-1274	1.9		
20	The Emergency Coma Scale as an alternative to the Glasgow Coma Scale. <i>American Journal of Emergency Medicine</i> , <b>2011</b> , 29, 821-2	2.9		

19	Single Centre, Retrospective Study to Evaluate Treatment Outcomes Following Tyrosine Kinase Inhibitor for Chronic Gvhd Treatment Including Ruxolitinib, Ibrutinib and Imatinib. <i>Blood</i> , <b>2020</b> , 136, 17	-1 <sup>2</sup> ·2
18	Allogeneic Transplant Can Abrogate the Relapse Risk in the Patients with Detectable Measureable Residual Disease By Multicolor Flow-Cytometry at the Time of Assessment of Acute Myeloid Leukemia Patients in First Remission. <i>Blood</i> , <b>2020</b> , 136, 36-37	2.2
17	Increased Risk of Secondary Malignancy Associated with the Use of Azathioprine for Chronic Graft-Versus-Host Disease Treatment. <i>Blood</i> , <b>2020</b> , 136, 1-2	2.2
16	ATG and Post-Transplant Cyclophosphamide Do Not Abrogate the Inferior Outcome Risk Conferred By HLA-land HLA-B Mismatched Unrelated Donors. <i>Blood</i> , <b>2020</b> , 136, 31-31	2.2
15	Donor Selection May Predict Improved Survival Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Chronic Myelomonocytic Leukemia - Experience from a Tertiary Care Centre. <i>Blood</i> , <b>2020</b> , 136, 23-24	2.2
14	Update of Multicenter, Retrospective Evaluation of Overall Response and Failure Free Survival Following Ruxolitinib Therapy for Heavily Pre-Treated Chronic Gvhd Patients with Steroid-Failure: A Proposal of Risk Score Model for Failure-Free Survival. <i>Blood</i> , <b>2021</b> , 138, 3905-3905	2.2
13	Single Centre, Retrospective Analysis of Extracorporeal Photopheresis (ECP) Therapy in the Patients Who Are Heavily Pre-Treated for Steroid Resistant Chronic Graft-Versus-Host Disease (GVHD). <i>Blood</i> , <b>2021</b> , 138, 1806-1806	2.2
12	Propensity Score Matching Analysis Comparing Extracorporeal Photopheresis (ECP) Vs Best Available Therapy in Third Line or Later Treatment of Chronic Graft-Versus-Host Disease (cGVHD). <i>Blood</i> , <b>2021</b> , 138, 3896-3896	2.2
11	Propensity Score Matching Analysis Comparing Ruxolitinib Vs Historical Controls in 2 nd Line or Beyond Treatment for Chronic Gvhd after Therapy Failure. <i>Blood</i> , <b>2021</b> , 138, 1805-1805	2.2
10	Frailty Scale for Outcome Predictions in Hematopoietic Cell Transplanted Adults. <i>Blood</i> , <b>2021</b> , 138, 110	0-12110
10	Frailty Scale for Outcome Predictions in Hematopoietic Cell Transplanted Adults. <i>Blood</i> , <b>2021</b> , 138, 110  Impact of Age on Hospitalization and Readmission on Post Allogeneic Stem Cell Transplantation Outcome, Single Center Experience. <i>Blood</i> , <b>2021</b> , 138, 4122-4122	2.2
	Impact of Age on Hospitalization and Readmission on Post Allogeneic Stem Cell Transplantation	
9	Impact of Age on Hospitalization and Readmission on Post Allogeneic Stem Cell Transplantation Outcome, Single Center Experience. <i>Blood</i> , <b>2021</b> , 138, 4122-4122  Largest Single Center Experience Using Dual T-Cell Depletion with ATG and Ptcy for Gvhd	2.2
9	Impact of Age on Hospitalization and Readmission on Post Allogeneic Stem Cell Transplantation Outcome, Single Center Experience. <i>Blood</i> , <b>2021</b> , 138, 4122-4122  Largest Single Center Experience Using Dual T-Cell Depletion with ATG and Ptcy for Gvhd Prophylaxis in Peripheral Blood RIC Allo-HSCT. <i>Blood</i> , <b>2019</b> , 134, 3344-3344  Reduced Intensity Conditioning and Dual T-Cell Modulation Improves Gvhd Free, Relapse Free Survival in AML Patients Compared with Myeloablative Conditioning. <i>Blood</i> , <b>2019</b> , 134, 4590-4590  Risk Factors for Primary and Secondary Graft Failure in Allogenic Hematopoietic Cell Transplantation: A Single Center Study. <i>Blood</i> , <b>2019</b> , 134, 2046-2046	2.2
9 8 7	Impact of Age on Hospitalization and Readmission on Post Allogeneic Stem Cell Transplantation Outcome, Single Center Experience. <i>Blood</i> , <b>2021</b> , 138, 4122-4122  Largest Single Center Experience Using Dual T-Cell Depletion with ATG and Ptcy for Gvhd Prophylaxis in Peripheral Blood RIC Allo-HSCT. <i>Blood</i> , <b>2019</b> , 134, 3344-3344  Reduced Intensity Conditioning and Dual T-Cell Modulation Improves Gvhd Free, Relapse Free Survival in AML Patients Compared with Myeloablative Conditioning. <i>Blood</i> , <b>2019</b> , 134, 4590-4590  Risk Factors for Primary and Secondary Graft Failure in Allogenic Hematopoietic Cell Transplantation: A Single Center Study. <i>Blood</i> , <b>2019</b> , 134, 2046-2046  No Impact of Donor® Age-Related Clonal Hematopoiesis (ARCH) Observed on Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation: Result from Bar-Coded Error Corrected Sequencing in 33 Gene Mutations on 372 Pairs of Donor and Recipient. <i>Blood</i> , <b>2019</b> ,	2.2 2.2
9 8 7	Impact of Age on Hospitalization and Readmission on Post Allogeneic Stem Cell Transplantation Outcome, Single Center Experience. <i>Blood</i> , <b>2021</b> , 138, 4122-4122  Largest Single Center Experience Using Dual T-Cell Depletion with ATG and Ptcy for Gvhd Prophylaxis in Peripheral Blood RIC Allo-HSCT. <i>Blood</i> , <b>2019</b> , 134, 3344-3344  Reduced Intensity Conditioning and Dual T-Cell Modulation Improves Gvhd Free, Relapse Free Survival in AML Patients Compared with Myeloablative Conditioning. <i>Blood</i> , <b>2019</b> , 134, 4590-4590  Risk Factors for Primary and Secondary Graft Failure in Allogenic Hematopoietic Cell Transplantation: A Single Center Study. <i>Blood</i> , <b>2019</b> , 134, 2046-2046  No Impact of Donorß Age-Related Clonal Hematopoiesis (ARCH) Observed on Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation: Result from Bar-Coded	2.2 2.2 2.2
<ul><li>9</li><li>8</li><li>7</li><li>6</li><li>5</li></ul>	Impact of Age on Hospitalization and Readmission on Post Allogeneic Stem Cell Transplantation Outcome, Single Center Experience. <i>Blood</i> , <b>2021</b> , 138, 4122-4122  Largest Single Center Experience Using Dual T-Cell Depletion with ATG and Ptcy for Gvhd Prophylaxis in Peripheral Blood RIC Allo-HSCT. <i>Blood</i> , <b>2019</b> , 134, 3344-3344  Reduced Intensity Conditioning and Dual T-Cell Modulation Improves Gvhd Free, Relapse Free Survival in AML Patients Compared with Myeloablative Conditioning. <i>Blood</i> , <b>2019</b> , 134, 4590-4590  Risk Factors for Primary and Secondary Graft Failure in Allogenic Hematopoietic Cell Transplantation: A Single Center Study. <i>Blood</i> , <b>2019</b> , 134, 2046-2046  No Impact of Donor® Age-Related Clonal Hematopoiesis (ARCH) Observed on Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation: Result from Bar-Coded Error Corrected Sequencing in 33 Gene Mutations on 372 Pairs of Donor and Recipient. <i>Blood</i> , <b>2019</b> , 134, 4514-4514  A Retrospective Study of Venous Thromboembolism in Acute Leukemia Patients during Prolonged	2.2 2.2 2.2 2.2

Refined hepatic grading system in chronic graft-versus-host disease improves prognostic risk stratification of long-term outcomes. *European Journal of Haematology*, **2021**, 106, 508-519

3.8